Citi sees renewed momentum in healthcare dealmaking across Asia
Citi expects increased merger and acquisition (M&A) activity in Asia’s healthcare sector in 2026, with particular momentum in Chinese biopharma and cross-border multinational transactions. The outlook follows a series of recent healthcare deals where Citi advised on exclusive licensing partnerships and strategic restructurings, signalling a rebound in deal confidence after a cautious period.
The forecast highlights how healthcare is emerging as a priority sector for corporate expansion and portfolio realignment. As demographic pressures, innovation cycles, and global capital flows converge, Asia’s healthcare landscape is becoming a focal point for strategic M&A.
Why healthcare M&A is re-accelerating in Asia
Asia’s healthcare sector has undergone rapid transformation over the past decade. Aging populations, rising incomes, and improved access to care have expanded demand across pharmaceuticals, medical devices, and health services. At the same time, innovation in biologics, gene therapies, and digital health has reshaped competitive dynamics.
In recent years, regulatory uncertainty and valuation gaps slowed dealmaking. However, conditions are now shifting. Many companies face pressure to unlock value, streamline operations, or access new growth pipelines. As a result, strategic partnerships and acquisitions are regaining appeal.
China plays a central role in this rebound. Its biopharma sector has matured, producing assets with global relevance. Multinational companies increasingly view Chinese innovators as partners rather than competitors, especially through licensing and co-development structures.
Where Citi sees deal activity concentrating
Citi’s outlook points to biopharma licensing and cross-border acquisitions as key drivers of 2026 activity. Instead of full takeovers, many companies prefer licensing deals that provide access to innovation while limiting balance-sheet risk.
These structures allow multinational firms to expand pipelines quickly, while Asian companies gain global reach and funding. Citi’s advisory role in exclusive licensing arrangements reflects this growing preference for flexible deal models.
Beyond biopharma, healthcare services and medical technology also present opportunities. Companies seek scale, operational efficiency, and geographic diversification. Cross-border deals enable firms to enter new markets without building capabilities from scratch.
Citi also expects restructuring-driven transactions. Some healthcare groups may divest non-core assets to focus on high-growth segments, creating opportunities for private capital and strategic buyers.
Healthcare M&A reflects strategic necessity, not opportunism
The renewed M&A interest is not driven by short-term speculation. Instead, it reflects structural pressures within healthcare. Research costs are rising, product cycles are shortening, and competition for innovation is intense.
For many companies, partnering or acquiring is faster and less risky than internal development. Licensing deals, in particular, allow firms to share risk while accelerating time-to-market. This model suits Asia’s diverse regulatory and market environments.
Citi’s forecast suggests that banks with strong cross-border capabilities will play a critical role. Navigating regulatory frameworks, valuation expectations, and cultural differences requires deep regional expertise, especially in sensitive sectors like healthcare.
China’s biopharma sector as a deal catalyst
China’s biopharma industry stands out as a major catalyst for 2026 M&A activity. Years of investment have produced a pipeline of late-stage assets and innovative platforms. At the same time, some firms face capital constraints or strategic crossroads.
Multinational companies view these conditions as an opportunity. By entering licensing or acquisition agreements, they can access innovation while helping Chinese partners scale globally. This mutual benefit underpins Citi’s optimism around deal flow.
Importantly, these transactions often involve selective asset deals rather than full company sales. This trend allows founders and management teams to retain control while monetising specific technologies.
What increased healthcare M&A could mean for Asia
In the near term, increased deal activity may improve capital access for innovative healthcare firms. Licensing income and acquisition proceeds can fund further research and expansion.
Over the medium term, consolidation may reshape competitive landscapes. Stronger, better-capitalised players could emerge, improving efficiency and global competitiveness.
Longer term, cross-border healthcare M&A supports knowledge transfer and standardisation. As Asian innovations integrate into global pipelines, the region’s role in shaping future healthcare solutions will continue to expand.
A sector poised for strategic dealmaking
Citi’s prediction of stronger healthcare M&A activity in Asia underscores a sector entering a new phase of strategic realignment. Driven by innovation needs, demographic trends, and global expansion goals, healthcare companies are turning to partnerships and acquisitions as essential tools.
As 2026 unfolds, the pace and structure of these deals will offer insights into how Asia’s healthcare industry positions itself within the global ecosystem. Citi’s outlook suggests that the coming year may mark a turning point for multinational collaboration and sector-specific restructuring across the region.
